SCHEMBL25388587

SCHEMBL25388587

COC(=O)c1c(Cl)ncc([N+](=O)[O-])c1C

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.43
POLB P06746 3/20 0.43
MAPK1 P28482 2/20 0.43
SMN1; SMN2 Q16637 3/20 0.40
KMT2A Q03164 4/20 0.39
MEN1 O00255 3/20 0.39
LMNA P02545 3/20 0.39
ALDH1A1 P00352 3/20 0.39
KDM4E B2RXH2 2/20 0.39
TDP1 Q9NUW8 2/20 0.39
ABCC4 O15439 1/20 0.39
PLIN1 O60240 1/20 0.39
CACNA1F O60840 1/20 0.39
GMNN O75496 1/20 0.39
KCNK2 O95069 1/20 0.39
ABCB11 O95342 1/20 0.39
GSR P00390 1/20 0.39
TP53 P04637 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30562612 1.00 MAPT (0.43) MAPTPOLBMAPK1SMN1; SMN2KMT2A
SCHEMBL30867309 0.84 SMN1; SMN2 (0.41) MAPTPOLBMAPK1SMN1; SMN2KMT2A
SCHEMBL29804406 0.78 MAPK1 (0.40) MAPTPOLBMAPK1KMT2AMEN1
SCHEMBL24683113 0.78 MAPK1 (0.40) MAPTPOLBMAPK1KMT2AMEN1
SCHEMBL3710523 0.76 KMT2A (0.52) MAPTPOLBMAPK1SMN1; SMN2KMT2A
SCHEMBL9149365 0.76 TDP1 (0.42) MAPTSMN1; SMN2KMT2AMEN1ALDH1A1
SCHEMBL24683791 0.75 TSHR (0.37) MAPTMAPK1SMN1; SMN2KMT2AMEN1
SCHEMBL23118260 0.75 PDGFRB (0.44) MAPTPOLBMAPK1SMN1; SMN2KMT2A
SCHEMBL70813 0.75 MAPT (0.63) MAPTPOLBMAPK1KMT2AMEN1
SCHEMBL7594307 0.74 KMT2A (0.38) MAPTPOLBMAPK1SMN1; SMN2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4583867-A2 SODIUM CHANNEL BLOCKING COMPOUNDS, DERIVATIVES THEREOF, AND METHODS OF THEIR USE Latigo Biotherapeutics, Inc. (US) 2025-07-16 EP disclosed
US-20250154109-A1 SODIUM CHANNEL BLOCKING COMPOUNDS, DERIVATIVES THEREOF, AND METHODS OF THEIR USE LATIGO BIOTHERAPEUTICS, INC 2025-05-15 US disclosed
CN-119894509-A Sodium channel blocking compounds, derivatives thereof, and methods of use thereof 拉堤果生物医疗股份有限公司 2025-04-25 CN disclosed
WO-2025029890-A1 SODIUM CHANNEL BLOCKING COMPOUNDS, DERIVATIVES THEREOF, AND METHODS OF THEIR USE LATIGO BIOTHERAPEUTICS, INC. (US) 2025-02-06 WO disclosed
EP-4472966-A2 SODIUM CHANNEL BLOCKING COMPOUNDS, DERIVATIVES THEREOF, AND METHODS OF THEIR USE Latigo Biotherapeutics, Inc. (US) 2024-12-11 EP disclosed
WO-2024054622-A2 SODIUM CHANNEL BLOCKING COMPOUNDS, DERIVATIVES THEREOF, AND METHODS OF THEIR USE LATIGO BIOTHERAPEUTICS, INC. (US) 2024-03-14 WO disclosed
WO-2023150201-A2 SODIUM CHANNEL BLOCKING COMPOUNDS, DERIVATIVES THEREOF, AND METHODS OF THEIR USE LATIGO BIOTHERAPEUTICS, INC. (US) 2023-08-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250154109-A1 SODIUM CHANNEL BLOCKING COMPOUNDS, DERIVATIVES THEREOF, AND METHODS OF THEIR USE SCN8A, TRPV1, SCNN1A MAPT 2721/4885POLB 4691/4885MAPK1 2312/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.